CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2017—GenomeDx Biosciences launched its Decipher Bladder Cancer Classifier following the publication of a study in European Urology (Seiler R, et al. Epub ahead of print April 5, 2017) supporting its development and validation. The company believes Decipher Bladder is the first commercially available clinical assay to subtype muscle-invasive bladder cancer with a high degree of accuracy.
Molecular subtyping of MIBC may be used to better prioritize patients diagnosed with aggressive bladder cancer to pursue underutilized standard of care chemotherapy before bladder removal surgery.
GenomeDX Biosciences, 888-792-1601